Mineralys Therapeutics (MLYS) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Recursion Pharmaceuticals (RXRX) has outperformed Mineralys Therapeutics (MLYS) over the past year, losing 26.2% versus a loss of 40.7%. Recursion Pharmaceuticals is the larger company by market cap ($2.34 billion vs $2.07 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLYS | RXRX |
|---|---|---|
| Share price | $23.37 | $4.36 |
| Market cap | $2.07B | $2.34B |
| 1-day change | +4.42% | +10.38% |
| YTD return | -35.60% | +6.60% |
| 1-year return | -40.67% | -26.23% |
| 5-year return | — | -79.25% |
| EPS (TTM) | $-4.41 | $-1.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $74.68M |
| Revenue growth (YoY) | — | +26.92% |
| Net income (latest FY) | $-154.65M | $-644.76M |
| Gross margin | — | 4.99% |
| Operating margin | — | -867.87% |
| Net margin | — | -863.35% |
| 52-week high | $47.65 | $7.18 |
| 52-week low | $21.46 | $2.77 |
| Distance from 52-week high | -50.95% | -39.28% |
| Analyst consensus | none | none |
| Avg. price target upside | +107.53% | +65.60% |
| Average volume | 1.04M | 20.70M |
| Shares outstanding | 88.41M | 535.34M |
| Employees | 76 | 600 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RXRX has outperformed MLYS by 14.4 percentage points over the past year.
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Healthcare · Biotechnology · 76 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Healthcare · Biotechnology · 600 employees
MLYS vs RXRX FAQ
Which is bigger, Mineralys Therapeutics or Recursion Pharmaceuticals?
Recursion Pharmaceuticals (RXRX) is larger, with a market capitalization of $2.34B compared with $2.07B for Mineralys Therapeutics (MLYS).
Which stock has performed better over the past year, MLYS or RXRX?
RXRX returned -26.23% over the past 12 months, compared with -40.67% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Mineralys Therapeutics and Recursion Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.